2026 oncology meetings
SITC, ESMO, ASCO, AACR and ASH 2026. 285 abstracts found by web research and verified against a source page so far, plus each meeting's journal supplement searched live through Crossref where it is indexed. Titles and metadata only.
SITC
SITC Annual Meeting 2026
4–8 Nov 2026, Phoenix
18
verified abstracts in 1 area
ESMO
ESMO Congress 2026
23–27 Oct 2026, Madrid
146
verified abstracts in 8 areas
ASCO
ASCO Annual Meeting 2026
29 May – 2 Jun 2026, Chicago
13
verified abstracts in 1 area
AACR
AACR Annual Meeting 2026
17–22 Apr 2026, San Diego
10
verified abstracts in 1 area
ASH
ASH Annual Meeting 2026
12–15 Dec 2026, New Orleans
98
verified abstracts in 4 areas
175 of 285 verified abstracts were confirmed on a page we fetched ourselves
Verified abstracts per 2026 meeting, split by how each row was checked. The rest match the text Parallel saved from a page that blocks automated access, mostly ESMO's congress platform.
Found on the cited source pageFound on a second fetched pageMatches only the excerpt saved from a page we could not re-fetch
Rows that failed every check were dropped and are not counted. Source: data/meetings in the project repository, each row linked to its source page.
ASH Annual Meeting 2026
12–15 Dec 2026, New Orleans · Blood 148 (Supplement 1)
The meeting is in December. Regular abstracts have been public since 4 Nov 2026 but the Blood supplement was not in Crossref on 11 Nov, so ASH abstracts here come from web research. Late-breaking abstracts are embargoed until 7 Dec and are not shown.
- 228Oral presentation
- 386Oral presentation
- 388Oral presentationRevumenib as pre-emptive therapy for measurable residual disease in NPM1 mutated or KMT2A-rearranged AML: Update from the ALLG AMLM26 intercept platform trialALLG AMLM26 interceptrevumenibVerified on source pageonlineprogram.hematology.org
- 502Oral presentationMeasurable residual disease detection by RT-qPCR for pediatric acute myeloid leukemiaAnushka Walia, MDVerified on source pageonlineprogram.hematology.org
- 661Oral presentation
- 662Oral presentationAzacitidine, venetoclax, and revumenib in newly diagnosed NPM1-mutated (NPM1m) or KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML): Final analysis of beat AML phase 1b studyJoshua F. Zeidner, MDbeat AMLazacitidinevenetoclaxrevumenibVerified on source pageonlineprogram.hematology.org
- 901Oral presentation
- 906Oral presentationUpdated results from cladribine, idarubicin, and cytarabine (CLIA) in combination with venetoclax in younger newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase II studyFieke W Hoff, MD, PhDCLIAcladribineidarubicincytarabinevenetoclaxVerified on source pageonlineprogram.hematology.org
- 1012Oral presentationVenetoclax plus three-day multi-frequency decitabine (DEC3-VEN) versus azacitidine plus venetoclaxDEC3-VENvenetoclaxdecitabineazacitidineVerified on source pageonlineprogram.hematology.org
- 1637Poster
- 1642PosterIvosidenib + azacitidine in newly diagnosed mIDH1 AML: The ongoing ALIDHE study confirms efficacy and safety in clinical practiceALIDHEivosidenibazacitidineVerified on source pageonlineprogram.hematology.org
- 1645PosterFLAG-ida, venetoclax, and FLT3 inhibitor combination therapy in newly diagnosed FLT3-mutated AML: High CR/CRi rates including in ELN adverse-risk diseaseFLAG-idavenetoclaxFLT3 inhibitorVerified on source pageonlineprogram.hematology.org
- 1647PosterVenetoclax, azacitidine, and homoharringtonine (VAH) in newly diagnosed acute myeloid leukemia: A propensity score-matched comparison with VA and IA regimensVAHvenetoclaxazacitidinehomoharringtonineVerified on source pageonlineprogram.hematology.org
- 1653PosterVenetoclax and azacitidine with or without idarubicin in fit newly diagnosed AML: A real-world risk-adapted study of 165 casesvenetoclaxazacitidineidarubicinVerified on source pageonlineprogram.hematology.org
- 1655PosterA safety run-in of decitabine/cedazuridine, venetoclax, and enasidenib for newly diagnosed IDH2-mutated AML: The myelomatch MM1OA-S03 studymyelomatch MM1OA-S03decitabine/cedazuridinevenetoclaxenasidenibVerified on source pageonlineprogram.hematology.org
- 1OtherSuperior event-free survival with ivosidenib plus intensive chemotherapy in newly diagnosed IDH1-mutated AML: Results from the phase 3 HOVON150/AMLSG29-18 trialBas J Wouters, MD, PhDHOVON150/AMLSG29-18ivosidenibcytarabinedaunorubicinmitoxantroneVerified on source pageonlineprogram.hematology.org
- 91Oral presentation
- 92Oral presentation
- 93Oral presentationAdditional somatic mutations detected by serial single-molecule molecular inversion probe sequencing in a prospective cohort of newly diagnosed chronic myeloid leukemia: Insights on mutational dynamics from the prospective TCGA-GTA registryMaria Perusini, MD, MscVerified on source pageonlineprogram.hematology.org
- 94Oral presentationImmune surveillance after a second TKI stop in CML: Dasatinib-associated CD4+ T-cell modulation and tfr duration — first findings from the DASTOP2 studyPakize Ak, MSDASTOP2dasatinibVerified on source pageonlineprogram.hematology.org
- 95Oral presentationFrontline therapy with tyrosine kinase inhibitors (TKIs) may modify the frequency of mutated ASXL1 and the cell lineage in blast Phase (BP) CML: Insights from the international CML foundation (iCMLf) genomics alliance on the Harmony PlatformSusan Branford, PhDVerified on source pageonlineprogram.hematology.org
- 96Oral presentationLongitudinal myeloid-panel sequencing reveals a diverse spectrum of somatic mutation dynamics in asciminib-treated chronic myeloid leukemiaAna Flavia Patiño IV, MDasciminibVerified on source pageonlineprogram.hematology.org
- 1980Poster
- 1981PosterA dasatinib-enhanced adaptive natural killer cell therapy against TKI-resistant blast crisis chronic myeloid leukemiaVaidehi Krishnan, PhDdasatinibVerified on source pageonlineprogram.hematology.org
- 1982Poster
- 1984PosterPhase II trial of dasatinib in combination with ASTX727 in patients with newly diagnosed chronic myeloid leukemiaGeorgio Medawar, MDdasatinibASTX727Verified on source pageonlineprogram.hematology.org
- 1985Poster
- 1986PosterAsciminib once or twice daily demonstrates sustained efficacy, stable patient-reported outcomes, and favorable safety in patients with chronic myeloid leukemia resistant or intolerant to 2 or more tyrosine kinase inhibitors: Final results of the ASC4OPT studyAndreas Hochhaus, MDASC4OPTasciminibVerified on source pageonlineprogram.hematology.org
- 1987PosterWeek 96 interim analysis (IA) of efficacy and safety results in the Phase 2 ASC2ESCALATE trial: Asciminib (ASC) in patients (pts) with chronic myeloid leukemia in chronic Phase (CML-CP) after 1 prior tyrosine kinase inhibitor (TKI)Ehab Atallah, MDASC2ESCALATEasciminibVerified on source pageonlineprogram.hematology.org
- 1988PosterEfficacy and safety of vamotinib versus high-dose imatinib in patients with chronic-phase CML resistant to standard-dose imatinib: 24-month Results of a multicenter randomized phase III studyAnna Turkina, MDvamotinibimatinibVerified on source pageonlineprogram.hematology.org
- 1989PosterOne-step single-molecule countable PCR enables cis/trans phasing of BCR-ABL1 compound mutations in TKI-resistant CMLYulei Shang, Ph.DVerified on source pageonlineprogram.hematology.org
- 1990Poster
- 1992Poster
- 1993Poster
- 1994PosterImpaired DNAM-1/NKp80 NK-cell activation and T-cell exhaustion at diagnosis precede suboptimal early molecular response in CMLLarissa Sarri Binelli SrVerified on source pageonlineprogram.hematology.org
- 1995PosterShort-course pomalidomide for maintaining treatment-free remission in CML-chronic Phase after TKI discontinuation: Early results of an ongoing Phase II trialHasmukh Jain, MDpomalidomideVerified on source pageonlineprogram.hematology.org
- 1996PosterAssociation of somatic mutations with long-term outcomes of ponatinib treatment in chronic Phase chronic myeloid leukemia.Olga Kulemina, MDponatinibVerified on source pageonlineprogram.hematology.org
- 1997Poster
- 1998Poster
- 3743PosterValidation of a prognostic score in blast phase CML: A cure CML consortium analysisAkriti G Jain, MD, FACPVerified on source pageonlineprogram.hematology.org
- 3744PosterDeep molecular response and treatment-free remission with dasatinib plus venetoclax in newly diagnosed chronic myeloid leukemiaDany Nassar, MDdasatinibvenetoclaxVerified on source pageonlineprogram.hematology.org
- 3745PosterLong-term outcomes with vodobatinib in heavily pre-treated chronic Phase CML: Phase 1/2 study analysisJorge Cortes, MDvodobatinibVerified on source pageonlineprogram.hematology.org
- 3759Poster
- 5511PosterCD19-directed CAR T-cell therapy with brexucabtagene autoleucel or obecabtagene autoleucel produces durable remission for CML patients in lymphoid blast phase: A rocca consortium multicenter analysisSinan Cetin, MDbrexucabtagene autoleucelobecabtagene autoleucelponatinibasciminibVerified on source pageonlineprogram.hematology.org
- 6333PosterRacial disparities in survival outcomes in CML in the era of expanding TKI availability: A two-decade, SEER population-based analysis (2001–2023)Muhammad Alamgir Khan, MDVerified on source pageonlineprogram.hematology.org
Other leukemias (ALL, CLL)
23 verified · pulled 2026-11-11- 254Oral presentation
- 255Oral presentation
- 256Oral presentation
- 257Oral presentation
- 258Oral presentationBCL2 mutations other than G101V dominate the landscape of venetoclax-resistance mutations in CLL treated in the current eraConstantine S. Tam, MD, MBBSvenetoclaxrituximabVerified on source pageonlineprogram.hematology.org
- 370Oral presentationLck regulates RNA polymerase II-dependent AP-1/BCL-xl transcriptional programs and therapeutic response to dasatinib in T-cell acute lymphoblastic leukemia.Huanbin Zhao, PhDdasatinibS63845Verified on source pageonlineprogram.hematology.org
- 535Oral presentationMRD-guided ibrutinib with venetoclax is superior to ibrutinib monotherapy and FCR in treatment naive CLL and may lead to functional cure in treatment naïve CLL: Results of randomised adapted Phase III FLAIR trial with median follow-up of 74 monthsTalha Munir, MBBS, MRCP, PhDFLAIRibrutinibvenetoclaxfludarabinecyclophosphamideVerified on source pageonlineprogram.hematology.org
- 536Oral presentation
- 537Oral presentation
- 538Oral presentationOutcomes of younger (= 55 years) compared with older (> 55 years) patients with chronic lymphocytic leukemia: A pooled analysis of prospective Phase II and III trials conducted by the German CLL study groupLéa MazotCLL2BAG; CLL2BIO; CLL2BIG; CLL2GIVe; CLL14; CLL13fludarabinecyclophosphamiderituximabchlorambucilVerified on source pageonlineprogram.hematology.org
- 539Oral presentationSix-year follow-up results of a multicenter, Phase 2 study of minimal residual disease (MRD)-guided acalabrutinib, venetoclax, obinutuzumab (AVO) in a population of previously untreated patients with CLL enriched for high-risk diseaseChristine Ryan MDAVOacalabrutinibvenetoclaxobinutuzumabVerified on source pageonlineprogram.hematology.org
- 540Oral presentationAcalabrutinib plus venetoclax vs venetoclax plus obinutuzumab in patients with previously untreated chronic lymphocytic leukemia: Interim results from the randomized, global, phase 3 MAJIC studyMatthew S Davids MD MMScMAJICacalabrutinibvenetoclaxobinutuzumabVerified on source pageonlineprogram.hematology.org
- 559Oral presentation
- 891Oral presentationPredictors of acute neurotoxicity in childhood acute lymphoblastic leukemia: Results from the DFCI ALL Consortium protocols 05-001,11-001 and 16-001Jing Wen, MD, PhDDFCI ALL Consortium protocols 05-001, 11-001, and 16-001high-dose methotrexateintrathecal chemotherapyVerified on source pageonlineprogram.hematology.org
- 892Oral presentation
- 894Oral presentation
- 1534PosterVascular adverse events during response-adapted ponatinib therapy with institutional thromboprophylaxis in Philadelphia chromosome–positive acute lymphoblastic leukemiaNooredeen IsbeihponatinibenoxaparinaspirinapixabanVerified on source pageonlineprogram.hematology.org
- 3537PosterDeterminants of long-term outcomes in hairy cell leukemia: The trinetx experienceJames NoyesVerified on source pageonlineprogram.hematology.org
- 3873Poster
- 3878Poster
- 3908Poster
- 3911Poster
- 5084PosterBlinatumomab responses and single-cell immune heterogeneity in pediatric B-ALL with MRD-defined high relapse risk: A single-center prospective studyRuidong Zhang, PhDblinatumomabVerified on source pageonlineprogram.hematology.org
- 115OralAnitocabtagene autoleucel following induction therapy in newly diagnosed multiple myeloma: Early safety, response, and MRD Results from the phase 2 GEM-anitofirst studyMaria-Victoria Mateos JrGEM-anitofirstanitocabtagene autoleucelVerified on source pageonlineprogram.hematology.org
- 116Oral
- 117Oral
- 118OralDeep and durable responses achieved with CB-011, an off-the-shelf CAR-T cell therapy, for heavily pretreated patients with relapsed/refractory multiple myeloma (CaMMouflage trial)Adriana RossiCaMMouflageCB-011Verified on source pageonlineprogram.hematology.org
- 119Oral
- 120OralGPRC5D expression and locus integrity in relapsed/refractory multiple myeloma treated with arlocabtagene autoleucel in a first-in-human Phase 1 trialSafiyyah Ziyadarlocabtagene autoleucelVerified on source pageonlineprogram.hematology.org
- 265Oral
- 266Oral
- 267OralSonrotoclax in combination with dexamethasone and daratumumab for t(11;14) relapsed/refractory multiple myeloma: Preliminary safety and efficacy results from the phase 1b/2 BGB-11417-105 studyBinod DhakalBGB-11417-105sonrotoclaxdexamethasonedaratumumabVerified on source pageonlineprogram.hematology.org
- 268OralSafety and preliminary efficacy of vemzatatug vedotin (AZD0305), a first-in-class novel antibody-drug conjugate targeting GPRC5D, in patients with relapsed/refractory multiple myeloma: Results from a phase 1/2 studyAmrita Krishnanvemzatatug vedotin (AZD0305)Verified on source pageonlineprogram.hematology.org
- 269Oral
- 270OralFirst-in-human phase 1/2a study of pamlectabart tismanitin (HDP-101), an amanitin-based BCMA-targeting antibody-drug conjugate (ADC): Recommended phase 2 dose (RP2D) selection and preliminary antitumor activity in relapsed/refractory multiple myeloma (RRMM)Marc-Steffen Steffen RaabHDP-101-01pamlectabart tismanitin (HDP-101)Verified on source pageonlineprogram.hematology.org
- 421OralFirst- and only-in-class CD38xBCMAxCD3 trispecific T-cell engager ISB-2001 (ABBV-2001): Updated Phase 1 (TRIgnite-1) study data demonstrate robust efficacy and tolerability in relapsed/refractory multiple myeloma (RRMM)Binod DhakalTRIgnite-1ISB-2001 (ABBV-2001)Verified on source pageonlineprogram.hematology.org
- 422OralSustained MRD-negativity with teclistamab-based treatment in transplant-eligible, newly diagnosed multiple myeloma in the phase 2 GMMG-HD10/DSMM-XX (MajesTEC-5) trialNiels WeinholdGMMG-HD10/DSMM-XX (MajesTEC-5)teclistamabVerified on source pageonlineprogram.hematology.org
- 423OralENTRUST-IFM/PETHEMA: Preliminary results of the phase 2 portion of a phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of Etentamig and daratumumab in frail transplant-ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM)Salomon ManierENTRUST-IFM/PETHEMAetentamigdaratumumabVerified on source pageonlineprogram.hematology.org
- 424Oral
- 425OralCevostamab consolidation following BCMA CAR T cell therapy: primary endpoint analysis of the phase 2 “STEM” (Sequential T Cell-Engagement for Myeloma) trialAdam D. CohenSTEM (Sequential T Cell-Engagement for Myeloma)cevostamabVerified on source pageonlineprogram.hematology.org
- 426OralPrimary Analysis of the phase 3 randomized MonumenTAL-6 study of teclistamab (Tec) plus talquetamab (Tal) or Tal plus pomalidomide (Pom) vs investigator's choice of elotuzumab, Pom and dexamethasone (EPd) or Pom, bortezomib, and dexamethasone (PVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) and 1–4 prior lines of therapy (LOT)Verified on source pageonlineprogram.hematology.org
- 931OralSingle-cell profiling reveals Tumor–Marrow biological penetrance and actionable target programs in high-risk multiple myelomaJunia Vieira dos SantosVerified on source pageonlineprogram.hematology.org
- 2796PosterMelflufen plus dexamethasone for relapsed/refractory multiple myeloma, including patients previously exposed to immunotherapy: Real-world outcomes from a spanish registry (amhh)David Martínez-Campuzano SrmelflufendexamethasoneVerified on source pageonlineprogram.hematology.org
- 5740PosterSecond primary malignancies (SPM) after transplantation for multiple myeloma: Risk continues to increase beyond 10 yearsVismay DeshaniVerified on source pageonlineprogram.hematology.org
- 5741Poster
- 5742Poster
- 5743PosterThe double dip: Identifying Critical Time Points for cytopenia after bispecific antibody therapyKristina NasrVerified on source pageonlineprogram.hematology.org
- 5744PosterHematologic improvement following weekly intravenous immunoglobulin (IVIG) for prolonged cytopenias after T-cell redirecting therapy for multiple myelomaMichelle Rudshteyn Korostinintravenous immunoglobulin (IVIG)Verified on source pageonlineprogram.hematology.org
- 5745PosterSafety and outcomes of combined radiation therapy with bispecific antibodies in relapsed/refractory multiple myelomaPatrick GouldVerified on source pageonlineprogram.hematology.org
- 5746Poster
- 5747Poster
- 5748Poster
- 5749Poster